Facility builds and retrofits are a leading indicator of which companies will be manufacturing which products, and where, in two to five years. Until 2017, the FDA approved approximately 22 new medicines per year. Beginning that year approvals jumped to the 50-plus range, which does not include several products (and tests) released under emergency use authorizations.
Facility projects also reveal something about a potentially new business model emerging for therapeutic biotech—one that emphasizes value and quality, perhaps, rather than the blockbuster model whose success is based on sales volume.
Read the complete article here.